Recertification (MOC) Review Course Webcast (2017): Other Male Sexual Dysfunction: Priapism and Premature Ejaculation

The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically-specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam. The course will model the changes to the Recertification Exam by covering core/general urology on the first day followed by a pre-selected breakout in one of four areas on the second day. Breakout sessions include oncology/urinary diversion; calculi, obstruction, endourology and laparoscopy; andrology, impotenence, infertility and infection; and female urology, incontinence, voiding dysfunction and reconstruction. Sample multiple choice practice questions as well as case based discussions and debates will be utilized to prepare attendees for the upcoming Recertification Examination. For more information on the changes to the Recertification Exam, please visit www.abu.org/recertification.

Target Audience

This program is designed for:

  • Practicing urologists preparing for the Recertification (MOC) Examination.

Learning Objectives

Upon completion of this course, participants will be able to:

  1. Review generally accepted urological practices for superior patient care
  2. Discuss a core knowledge of urology necessary for taking the Recertification Examination
  3. Examine the most recent changes and additions to the AUA guidelines
  4. Review the appropriate indications for and use of diagnostic tests in the evaluation and management of male infertility.
  5. Develop the ability to make guideline-based decisions regarding the evaluation and management of male sexual disorders, including erectile dysfunction, Peyronie’s disease and priapism.
  6. Discuss the evaluation and appropriate treatment indications of hypogonadism, with enhanced ability to review the risks and benefits of testosterone replacement therapy.
  7. Enhance ability to provide guideline-based vasectomy care.
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
Course opens: 
09/16/2017
Course expires: 
09/16/2020
Part of: 
Recertification (MOC) Review Course Webcast: Andrology, Infertility, Erectile Dysfunction and Infection (2017)
Rating: 
0

Faculty Disclosures
Course Directors:
Badrinath Konety, MD, MBA: Amgen: Meeting Participant or Lecturer; Axogen Inc.: Consultant or Advisor; Centocor Ortho Biotech: Consultant or Advisor; Spectrum Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial; Allergan: Consultant or Advisor; Endo Pharmaceuticals: Consultant or Advisor; MDx Health: Consultant or Advisor; Spectrum: Scientific Study or Trial; NxThera Inc: Consultant or Advisor; MDX Health: Consultant or Advisor; Genentech/Roche: Scientific Study or Trial; Dendreon: Consultant or Advisor, Scientific Study or Trial; Photocure Inc: Scientific Study or Trial , Consultant or Advisor; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Takeda Inc: Consultant or Advisor
Timothy Averch, MD, FACS: Bard Urologic: Consultant or Advisor, Meeting Participant or Lecturer; Cook Urological, Inc: Consultant or Advisor; Canadian Journal of Urology: Health Publishing; Journal of Endourology: Health Publishing; Journal of Urology: Health Publishing
 
Course Faculty:
Thomas Walsh, MD: Counsyl Genetics: Consultant or Advisor; American Medical Systems: Consultant or Advisor, Meeting Participant or Lecturer; Coloplast: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Consultant or Advisor; Seattle Sperm Bank: Consultant or Advisor; Endo Health Solutions: Consultant or Advisor, Meeting Participant or Lecturer; Auxillium Pharmaceuticals: Consultant or Advisor, Meeting Participant or Lecturer , Consultant or Advisor, Meeting Participant or Lecturer; Galapagos: Consultant or Advisor; Coloplast: Consultant or Advisor; Boston Scientific: Consultant or Advisor; Counsyl Genetics: Investment Interest
Tobias Kohler, MD, MPH: Actient: Consultant or Advisor, Meeting Participant or Lecturer; American Medical Systems: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Coloplast: Consultant or Advisor, Meeting Participant or Lecturer; Abbott: Scientific Study or Trial; Timm Medical: Consultant or Advisor; Auxilium: Meeting Participant or Lecturer; Lilly: Meeting Participant or Lecturer; Allergan: Meeting Participant or Lecturer; Abbvie: Scientific Study or Trial , Scientific Study or Trial; Lipocine: Consultant or Advisor; Abbvie: Consultant or Advisor, Scientific Study or Trial
Joseph Alukal , MD: Nothing to disclose
 
Planner Disclosures
Education Council
Timothy Charles Brand, M.D.: Nothing to disclose
Anthony A. Caldamone MD: Nothing to disclose
Peter Robert Carroll, MD, MPHL: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; Myriad Genetics: Scientific Study or Trial; Genomic Health: Scientific Study or Trial; Abbott Pharmaceuticals: Scientific Study or Trial; AUA Update: Leadership Position; Janssen Pharmaceutical Companies: Meeting Participant or Lecturer; Intuitive Surgical Inc.: Meeting Participant or Lecturer; Medivation/Astellas: Consultant or Advisor; Takeda Pharmaceutical Company: Meeting Participant or Lecturer; Astra Zeneca: Meeting Participant or Lecturer; Genome Dx: Consultant or Advisor; Intuitive: Meeting Participant or Lecturer; Genomic Health: Scientific Study or Trial; takeda: Meeting Participant or Lecturer; Teva Pharmaceutical Industries: Meeting Participant or Lecturer
Matthew S. Christman MD: Nothing to disclose
Jody Donaldson: Nothing to disclose
Shelby Englert: Nothing to disclose
Matthew Thomas Gettman, M.D.: COVR Medical: Consultant or Advisor; Intuitive Surgical: Consultant or Advisor; Exact Sciences: Scientific Study or Trial
Inderbir Singh Gill ,MD, M.Ch.: Hansen Medical: Investment Interest; EDAP: Consultant or Advisor , Consultant or Advisor; Mimic: Consultant or Advisor
Howard B. Goldman, MD: Johnson and Johnson: Consultant or Advisor, Meeting Participant or Lecturer; American Medical Systems: Consultant or Advisor; watson: Meeting Participant or Lecturer; allergan: Consultant or Advisor; johnson and johnson: Meeting Participant or Lecturer; pfizer: Consultant or Advisor, Meeting Participant or Lecturer; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor; Theracoat: Consultant or Advisor; Wellspect: Consultant or Advisor; Cook: Scientific Study or Trial; american medical systems: Consultant or Advisor, Meeting Participant or Lecturer; pfizer: Consultant or Advisor, Meeting Participant or Lecturer; axonics: Consultant or Advisor; astellas: Consultant or Advisor; Teva: Consultant or Advisor; TDoc: Consultant or Advisor; Teva: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; uroplasty: Consultant or Advisor, Meeting Participant or Lecturer
William C. Huang, MD: Consultant or Advisor; Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
William C. Hulbert Jr. MD: Nothing to disclose
Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Ferring Pharmaceuticals: Consultant or Advisor; Genentech Inc: Scientific Study or Trial; Pfizer: Other: Sponsored educational forum; Combat Medical: Consultant or Advisor, Scientific Study or Trial; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor; AstraZeneca: Consultant or Advisor; BioCancell: Consultant or Advisor; Nucleix: Scientific Study or Trial
Mark L. Jordan MD,FACS: Nothing to disclose
Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor , Scientific Study or Trial; Urologic Research: Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
Martin A. Koyle MD: Nothing to disclose
Yair Lotan ,MD: Alere: Scientific Study or Trial; abbott: Scientific Study or Trial; Danone: Consultant or Advisor, Scientific Study or Trial; endo: Meeting Participant or Lecturer; Metabolon: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; Predictive Biosciences: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial; Genomic Health : Scientific Study or Trial
Nicole Lara Miller ,MD: Lumenis: Meeting Participant or Lecturer; Storz: Meeting Participant or Lecturer; Boston Scientific: Meeting Participant or Lecturer; Lumenis: Meeting Participant or Lecturer; Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
Manoj Monga, MD, FACS: US Endoscopy: Consultant or Advisor; Thermadex: Consultant or Advisor; Percuvision: Consultant or Advisor; Histosonics: Consultant or Advisor; Taris Biomedical: Scientific Study or Trial; Xenolith: Scientific Study or Trial; practical reviews in urology: Health Publishing; CMS SCIP - representative for AUA: Leadership Position; endourology society: Leadership Position; indian american urological association: Leadership Position; ohio urological society: Leadership Position; journal of endourology: Health Publishing; indian journal of urology: Health Publishing; brazilian journal of urology: Health Publishing; Cook Urological: Meeting Participant or Lecturer; Mission Pharmacal: Meeting Participant or Lecturer; Coloplast: Consultant or Advisor; Olympus: Consultant or Advisor; Bard: Consultant or Advisor; Fortec: Other: Quality Assurance
Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Ethicon: Consultant or Advisor; Allergan: Health Publishing, Scientific Study or Trial; Medtronic: Consultant or Advisor; Allergan: Health Publishing, Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Pfizer: Health Publishing, Consultant or Advisor; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial; Pfizer: Consultant or Advisor; Ipsen: Consultant or Advisor; Ono: Consultant or Advisor; Theracoat: Consultant or Advisor; Pneumoflex: Consultant or Advisor; Pfizer: Consultant or Advisor; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Coloplast: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Uroplasty: Consultant or Advisor; American Medical Systems: Health Publishing, Consultant or Advisor, Scientific Study or Trial; Astellas: Health Publishing, Consultant or Advisor, Scientific Study or Trial
Christopher Porter, MD: Nothing to disclose          
Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer , Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Intuitive Surgical: Consultant or Advisor; Pacific Edge Biotechnology: Consultant or Advisor, Scientific Study or Trial
Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
Karl-Dietrich Sievert: AMS: Meeting Participant or Lecturer; Karl Storz: Meeting Participant or Lecturer; Photocure: Scientific Study or Trial; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
Joseph A. Smith Jr.,MD: Nothing to disclose
Ryan Patrick Terlecki, MD, FACS: Auxilium: Consultant or Advisor; Coloplast: Consultant or Advisor; American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
Edouard John Trabulsi, MD: Centocor: Consultant or Advisor, Meeting Participant or Lecturer; Amgen: Consultant or Advisor, Meeting Participant or Lecturer; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer; Medivation: Consultant or Advisor, Meeting Participant or Lecturer; Photocure: Consultant or Advisor; GenomeDx: Consultant or Advisor , Consultant or Advisor

Method of Participation
To claim CME credit/hours of participation for each webcast, the learner must complete to pre-test, view the webcast, complete the posttest passing with 80% accuracy and submit the evaluation.

Estimated time to complete this activity: 0.75 hours
 
Release Date: September, 2017
Expiration Date: September, 2020
 
Accreditation Statement
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.
Other Learners
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
Evidence Based Content
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

 
Off-label or Unapproved Use of Drugs or Devices
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
 
Reproduction Permission
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
 
AUA Privacy and Confidentiality Policy
 www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: cme@AUAnet.org

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Non-Physician Participation
Please login or register to take this course.